Search Results
Feb 24, 2026, 06:00 ET Brainomix Extends Series C Financing to $25.4M (£18.8M) to Support U.S. Expansion
confidence in our technology, our team, and the impact Brainomix 360 Stroke and e-Lung can have on patient care," said Dr Michalis Papadakis, CEO and co-founder of Brainomix. "Stroke care depends on speed, while lung fibrosis care requires early identification and consistent clinical decision-making
More news about: Brainomix
Feb 24, 2026, 01:44 ET Fractal Launches PiEvolve, an Evolutionary Agentic Engine for Autonomous Machine Learning and Scientific Discovery
Qure.ai, a global healthcare AI leader enhancing the rapid identification and management of tuberculosis, lung cancer, and stroke. Fractal's dedicated AI Research team is focused on foundational
More news about: Fractal Analytics Limited
Feb 24, 2026, 01:33 ET Fractal Launches PiEvolve, an Evolutionary Agentic Engine for Autonomous Machine Learning and Scientific Discovery
Qure.ai, a global healthcare AI leader enhancing the rapid identification and management of tuberculosis, lung cancer, and stroke. Fractal's dedicated AI Research team is focused on foundational
More news about: Fractal Analytics Limited
Feb 24, 2026, 01:25 ET Fractal Launches PiEvolve, an Evolutionary Agentic Engine for Autonomous Machine Learning and Scientific Discovery
Qure.ai, a global healthcare AI leader enhancing the rapid identification and management of tuberculosis, lung cancer, and stroke. Fractal's dedicated AI Research team is focused on foundational
More news about: Fractal Analytics Limited
Feb 23, 2026, 10:45 ET Extracorporeal Membrane Oxygenation Machine (ECMO) Market to Reach $793.7 Million, Globally, by 2033 at 4.6% CAGR: Allied Market Research
Growth in demand for extracorporeal membrane oxygenation (ECMO) in lung transplants. Opportunities
More news about: Allied Market Research
Feb 23, 2026, 08:55 ET Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat
breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms
More news about: Anixa Biosciences, Inc.
Feb 23, 2026, 08:30 ET IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026
liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver.ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its
More news about: IceCure Medical
Feb 23, 2026, 08:00 ET Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer
portfolio, providing further protection for various therapeutic combinations, including the Acclaim-3 clinical trial for the treatment of small cell lung cancer using REQORSA in combination with PD-L1 antibodies.
More news about: Genprex, Inc.
Feb 23, 2026, 08:00 ET Dark Places Big Screen Premiere Announced & Hits TUBI, Fawesome & More - Horror Movie News
here.With the recently released popularity of IRON LUNG by influencer Markiplier, the decision was made to push DARK PLACES into more big-screen showings throughout the New England area, with the hopes of
More news about: Cinema Epoch
Feb 22, 2026, 19:10 ET CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC
sugemalimab has received a new indication approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for stage III non-small cell lung cancer (NSCLC). This marks the second indication approved for the product in the UK.This approval is based on the GEMSTONE-301 study, a multicenter,
More news about: CStone Pharmaceuticals
Feb 21, 2026, 08:00 ET TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years
STELARA®, including: headache, seizures, confusion, and vision problems.Lung InflammationCases of lung inflammation have happened in some people who receive STELARA® and may be serious. These lung problems may need to be treated in a hospital. Tell your healthcare provider right
More news about: Johnson & Johnson
Feb 20, 2026, 16:05 ET TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on February 18, 2026, TransMedics granted non-qualified stock options to purchase an aggregate of 40,089
More news about: TransMedics Group, Inc.
Feb 20, 2026, 10:00 ET ALPHA-1 FOUNDATION ENGAGES MIAMI COMMUNICATIONS FIRM TO ACCELERATE FUNDRAISING
liver, with no cure to date. Lung-affected patients typically do not show symptoms until adulthood, when their lung function declines much more rapidly than in a typically aging adult. Patients are often diagnosed with emphysema and Chronic Obstructive Pulmonary Disease (COPD). Lung-affected patients are treated
More news about: The Weinbach Group, Inc.
Feb 20, 2026, 08:00 ET Zenocutuzumab Treatment Beyond Progression Demonstrates Continued Benefit in Patients with NRG1+ Non-Small Cell Lung Cancer: New Results from the eNRGy Trial
patients with advanced neuregulin 1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC). Results were presented at the 2026 International Association for the Study of Lung Cancer (IASLC) Targeted Therapies of Lung Cancer (TTLC) meeting. NRG1+ NSCLC is associated with low response rates
More news about: Partner Therapeutics, Inc.
Feb 19, 2026, 17:00 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer
reaction occurs, permanently discontinue RYBREVANT®.Interstitial Lung Disease/Pneumonitis RYBREVANT FASPRO™ and RYBREVANT® can cause severe and fatal interstitial lung disease (ILD)/pneumonitis.RYBREVANT FASPRO™ with LAZCLUZE®In
More news about: Johnson & Johnson
Feb 19, 2026, 16:02 ET GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results
cancer2,*. The Galleri test increases the number of cancers detected seven-fold when added to recommended screening for breast, cervical, colorectal and lung cancers, and has the lowest false positive rate of any MCED test on the market1,2,3,4,**. When a cancer signal is found, Galleri provides
More news about: GRAIL, Inc.
Feb 19, 2026, 16:01 ET Landmark NHS-Galleri Trial Demonstrates a Substantial Reduction in Stage IV Cancer Diagnoses, Increased Stage I and II Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection Rate
improvement in the overall cancer detection rate compared to standard of care screening alone in England for breast, colorectal, cervical and high risk lung cancer.Substantial increase in the absolute number of Stage I-II cancers in the 12 pre-specified deadly cancer types that are typically found
More news about: GRAIL, Inc.
Feb 19, 2026, 08:30 ET IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense®, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation
liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver.ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its
More news about: IceCure Medical
Feb 19, 2026, 08:19 ET Fractal launches Vaidya 2.0, outperforming leading frontier models on Healthcare AI Benchmarks
Qure.ai, a global healthcare AI leader enhancing the rapid identification and management of tuberculosis, lung cancer, and stroke. Fractal's dedicated AI Research team is focused on foundational
More news about: Fractal Analytics Limited
Feb 19, 2026, 08:10 ET Fractal launches Vaidya 2.0, outperforming leading frontier models on Healthcare AI Benchmarks
Qure.ai, a global healthcare AI leader enhancing the rapid identification and management of tuberculosis, lung cancer, and stroke. Fractal's dedicated AI Research team is focused on foundational
More news about: Fractal Analytics Limited
Feb 19, 2026, 07:58 ET Fractal launches Vaidya 2.0, outperforming leading frontier models on Healthcare AI Benchmarks
Qure.ai, a global healthcare AI leader enhancing the rapid identification and management of tuberculosis, lung cancer, and stroke. Fractal's dedicated AI Research team is focused on foundational
More news about: Fractal Analytics Limited
Feb 19, 2026, 07:00 ET Altesa BioSciences Closes Oversubscribed $75 Million Series B Financing to Transform Treatment of Chronic Lung Diseases
utilization, and lung function.About Altesa BioSciences, Inc.Altesa BioSciences is a clinical-stage pharmaceutical company, led by global experts in respiratory medicine and infectious diseases. We are dedicated to improving the lives of people with chronic lung diseases, like
More news about: Altesa Biosciences Inc.
Feb 19, 2026, 07:00 ET Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update
avium complex (MAC) lung disease who have not started antibiotics.Pending positive topline data from the ENCORE trial, Insmed plans to submit a supplementary new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for ARIKAYCE in all patients with MAC lung disease in the second
More news about: Insmed Incorporated
Feb 18, 2026, 17:43 ET Brayton Purcell LLP Has Secured Almost $200 million for Artificial Stone Fabrication Workers as Attention Intensifies on the Silicosis Crisis in California and Across the Nation
few years of exposure. Workers affected by the disease face profound medical challenges, including extensive lung scarring, oxygen dependence, and, in the most severe cases, the need for lung transplantation. Many are relatively young, with careers and family responsibilities cut short by a preventable
More news about: Brayton Purcell LLP
Feb 18, 2026, 13:03 ET Belay Diagnostics Announces the Validation of Summit™ 2.0 Comprehensive Genomic Profile Assay in Cerebrospinal Fluid (CSF)
primary and metastatic CNS tumors, including gliomas, astrocytomas, glioblastomas, medulloblastomas, lymphomas, and metastatic cancers originating from lung, breast, melanoma, and other solid tumors. The expanded content of Summit™ 2.0 further demonstrated improved detection yield compared to its prior generation assay, identifying clinically significant alterations in cases
More news about: Belay Diagnostics